《GreTai》BioFirst Vitreous Substitute obtained invention patent in Korea.The technique

 

 

 

 

 

 

 

 

 BioFirst, “Vitreous Substitute” obtained invention patent in Korea. BioFirst indicated that “Vitreous Substitute” had approved in U.S., Taiwan and Australia. Just got a notice from The Korean Intellectual Property Office and the expiration date of patent is 2030. The general manager said that it is the treasure of country and we are going to shine in the whole world. BioFirst had submitted a project to Ministry of Science and Technology, which plan to conduct the first production factory of Vitreous Substitute in Hsinchu Biomedical Science Park with authenticating global GMP premise. Based on market researching reports, the global market potential of BioFirst’s Vitreous Substitute can be up to 2 billion dollars per year. The technique of Vitreous Substitute from BioFirst is the first gelation product, which used in renal detachment recovery operations. Besides the patent in U.S., Australia, Taiwan and Korea, there are cases that are under review in ten more countries through the PCT.